• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Omeros Corporation

    10/31/25 11:05:31 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OMER alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Omeros Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    682143102

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    682143102


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    438,694.00
    7Sole Dispositive Power

    2,887,220.00
    8Shared Dispositive Power

    459,738.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,346,958.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.91 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Omeros Corp
    (b)Address of issuer's principal executive offices:

    201 Elliott Avenue West, Seattle, WA, 98119
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    682143102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3346958
    (b)Percent of class:

    4.91  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    438694

     (iii) Sole power to dispose or to direct the disposition of:

    2887220

     (iv) Shared power to dispose or to direct the disposition of:

    459738

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/31/2025
    Get the next $OMER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMER

    DatePrice TargetRatingAnalyst
    6/10/2025$9.00Buy
    H.C. Wainwright
    12/23/2024$36.00Buy
    D. Boral Capital
    11/14/2024$9.00Buy
    Rodman & Renshaw
    12/8/2022$12.00 → $2.00Buy → Neutral
    UBS
    11/8/2022$8.00 → $3.00Neutral → Underperform
    BofA Securities
    6/8/2022$12.00 → $4.00Buy → Neutral
    BofA Securities
    10/19/2021$19.00 → $12.00Buy
    HC Wainwright & Co.
    10/8/2021Neutral → Underweight
    JP Morgan
    More analyst ratings

    $OMER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omeros Announces First Commercial Sales of YARTEMLEA®

    — Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — Omeros Corporation (NASDAQ:OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpatient settings. YARTEMLEA is the first and only approved therapy for

    1/27/26 9:00:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

    – Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –  First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno

    12/24/25 9:00:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Demopulos Gregory A Md bought $25,200 worth of shares (15,000 units at $1.68) (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/21/23 8:11:35 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Demopulos Peter A Md bought $15,300 worth of shares (10,000 units at $1.53), increasing direct ownership by 5% to 208,516 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/17/23 9:46:20 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Omeros with a new price target

    H.C. Wainwright initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    6/10/25 8:09:22 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Omeros with a new price target

    D. Boral Capital initiated coverage of Omeros with a rating of Buy and set a new price target of $36.00

    12/23/24 7:27:28 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Omeros with a new price target

    Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    11/14/24 7:47:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    SEC Filings

    View All

    $OMER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form SCHEDULE 13G filed by Omeros Corporation

    SCHEDULE 13G - OMEROS CORP (0001285819) (Subject)

    1/30/26 2:19:55 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - OMEROS CORP (0001285819) (Filer)

    1/7/26 5:15:49 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - OMEROS CORP (0001285819) (Filer)

    12/29/25 6:08:56 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Finance & CAO Borges David J. sold $750,915 worth of shares (60,000 units at $12.52) and exercised 30,000 shares at a strike of $3.06, closing all direct ownership in the company (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    1/14/26 5:25:24 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, CEO & President Demopulos Gregory A Md gifted 600,000 shares and received a gift of 600,000 shares, decreasing direct ownership by 30% to 1,426,986 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    10/15/25 7:16:04 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman, CEO & President Demopulos Gregory A Md

    4 - OMEROS CORP (0001285819) (Issuer)

    7/1/25 5:32:34 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Leadership Updates

    Live Leadership Updates

    View All

    Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

    Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch

    10/19/23 8:30:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Financials

    Live finance-specific insights

    View All

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

    – Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –  First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno

    12/24/25 9:00:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

    Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wil

    11/11/25 8:30:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    3/27/24 2:47:02 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    2/14/24 6:05:17 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Omeros Corporation

    SC 13G - OMEROS CORP (0001285819) (Subject)

    2/13/24 5:12:07 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care